NCT00319137

An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine

A Randomized, Single-Blind, Single-Attack, Placebo-Controlled, Adaptive Design Study to Assess the Safety and Efficacy of Doses of 5-180 mg of the iNOS Inhibitor GW274150 in the Treatment of Acute Migraine During the Mild Headache Phase

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 126 (planned)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO. Reduction of NOS, and therefore NO, may be an effective technique for the treatment of migraine headache. GW274150 is a highly selective inhibitor of NOS and offers the potential of anti-inflammatory activity in migraine through a novel mechanism of action. The intent of this study is to investigate the safety and efficacy of GW274150 for the acute treatment of migraine headache.

Conditions

• Migraine Disorders
• Migraine

Interventions

Type	Name	Description
DRUG	GW274150

Timeline

• Start date: 2005-12-01
• First posted: 2006-04-27
• Last updated: 2012-06-04

Locations

5 sites across 2 countries: Australia, New Zealand